PHI with Basal ganglia calcification
How does this condition affect your private health insurance?
Kalzifikation der Basalganglien, also known as Fahr's disease or primary familial brain calcification (PFBC), is a rare neurological disorder characterized by abnormal calcium deposits in the basal ganglia and often other brain regions. These calcifications lead to a diverse range of symptoms, including movement disorders (e.g., parkinsonism, dystonia, chorea), cognitive impairment, psychiatric manifestations (e.g., depression, psychosis), and speech difficulties. The etiology can be genetic (familial) or secondary to various conditions such as hypoparathyroidism, infections, or mitochondrial disorders. Diagnosis relies on neuroimaging, typically CT scans, which clearly show the calcifications.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Often insidious, developing gradually over months or years.
Duration of Illness (Lifetime)
Chronic and typically progressive throughout the patient's lifetime.
Cost of Treatment (Initial)
Moderate to high (diagnostic imaging, specialist consultations, initial symptomatic medication).
Cost of Treatment (Lifetime)
High to very high (lifelong symptomatic management, supportive therapies, rehabilitation, regular monitoring).
Mortality Rate
Low; however, severe neurological complications can indirectly impact life expectancy.
Risk of Secondary Damages
High (progressive neurological deficits, cognitive decline, severe movement disorders, psychiatric conditions).
Probability of Full Recovery
Very low; the calcifications are generally irreversible, and the disease is often progressive.
Underlying Disease Risk
Variable; can be idiopathic/genetic (primary familial brain calcification) or secondary to metabolic disorders (e.g., hypoparathyroidism), infections, or toxic exposures.